Chen Y, et al. - Researchers conducted the study for investigating the role of oral erythromycin therapy in the treatment of pityriasis lichenoides (PL) and pityriasis lichenoides et varioliformis acuta (PLEVA) in children. They reported 16 pediatric patients with PL and systematically reviewed published literatures on erythromycin treatment response in pediatric PL patients, to observed the different treatment response to erythromycin in the pityriasis lichenoides chronica (PLC) and the PLEVA groups. Sixteen patients (8 with PLC and 8 with PLEVA) have been treated with erythromycin. For further descriptive analysis, a total of 34 children were included involving 16 from the studies, of which 12 had PLC and 22 had PLEVA. The authors concluded that erythromycin is effective and safe in the treatment of children with PL and was more effective in patients with PLEVA than PLC.